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TObjective: Patients with pathologic node-negative early lung cancer may be optimal candidates for sublobar
resection. We aimed to identify predictors of pathologic lymph node involvement in clinical stage IA lung ad-
enocarcinoma.
Methods: The data from a multicenter database of 502 patients with completely resected clinical stage IA lung
adenocarcinoma were retrospectively analyzed to determine the relationship between the lymph node metastasis
status and tumor size on high-resolution computed tomography (HRCT) or maximum standardized uptake value
(SUVmax) on [18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-
PET/CT). Revised SUVmax was used to correct interinstitutional discrepancies.
Results: In multivariate analyses, either a solid tumor size on HRCT (P¼ .001) or an SUVmax on FDG-PET/CT
(P ¼ .049) was an independent predictor of lymph node metastasis. The predictive criteria of pathologic node-
negative early lung cancer were a solid tumor size of less than 0.8 cm or an SUVmax of less than 1.5. Patients
who met the predictive criteria of pathologic node-negative disease had less pathologic invasiveness, such as
lymphatic, vascular, or pleural invasion (P< .001), and better disease-free survival (P< .0001) than those
who did not, and 86 (40.4%) of the 213 patients with T1b (2-3 cm) tumors met the predictive criteria.
Conclusions: Either a solid tumor size or an SUVmax was a significant independent predictor of nodal involve-
ment in clinical stage IA lung adenocarcinoma. The pathologic node-negative status criteria of a solid tumor size
of less than 0.8 cm on HRCT or an SUVmax of less than1.5 on FDG-PET/CT may be helpful for avoiding
systematic lymphadenectomy for clinical stage IA lung adenocarcinoma, even in cases of T1b (2-3 cm) tumor.
(J Thorac Cardiovasc Surg 2012;144:1365-71)Earn CME credits at
http://cme.ctsnetjournals.org
Recent advances in radiography, such as high-resolution
computed tomography (HRCT) and thewidespread practice
of low-dose helical computed tomography (CT) for screen-
ing of tumors, have resulted in an increase in the early
detection of smaller non–small cell lung cancer (NSCLC),
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The Journal of Thoracic and Carreported that the survival is similar in patients with small
peripheral NSCLC between those treated with
segmentectomy and those treated with lobectomy.1,4-8 In
determining the indications for sublobar resection,
prediction of the pathologic node-negative (pN0) status is
important.4-8 We9 previously reported that solid tumor
size on HRCT and maximum standardized uptake value
(SUVmax) on [18F]-fluoro-2-deoxy-D-glucose positron
emission tomography/computed tomography (FDG-PET/
CT) were useful for predicting pathologic invasiveness or
prognosis in clinical stage IA lung adenocarcinoma. We hy-
pothesized that solid tumor size on HRCT and SUVmax on
FDG-PET/CT had a predictive value for lymph node metas-
tasis. Therefore, we retrospectively investigated the preop-
erative predictive value of solid tumor size and SUVmax for
pN0 status to select optimal candidates for sublobar resec-
tion in clinical stage IA lung adenocarcinoma. The primary
end point of this study was lymph node involvement.PATIENTS AND METHODS
Patients
We enrolled 502 patients with clinical T1 N0 M0 stage IA lung adeno-
carcinoma from 4 institutions in Japan (Hiroshima University, Kanagawadiovascular Surgery c Volume 144, Number 6 1365
Abbreviations and Acronyms
CT ¼ computed tomography
DFS ¼ disease-free survival
FDG ¼ [18F]-fluoro-2-deoxy-D-glucose
GGO ¼ ground-glass opacity
HRCT ¼ high-resolution computed tomography
NSCLC ¼ non–small cell lung cancer
PET ¼ positron emission tomography
SUVmax ¼ maximum standardized uptake value
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SCancer Center, Cancer Institute Hospital, and Hyogo Cancer Center) be-
tween August 1, 2005, and December 31, 2009, to evaluate the significance
of FDG-PET/CT.10 The data from all 502 patients from this multicenter da-
tabase were retrospectively analyzed in the present study. HRCTand FDG-
PET/CT followed by curative R0 resection were performed for all patients
who were staged according to the TNM Classification of Malignant Tu-
mours, 7th edition.11 Mediastinoscopy or endobronchial ultrasonography
was not routinely performed because all patients received preoperative
HRCTand FDG-PET/CT; HRCT revealed no swelling of mediastinal or hi-
lar lymph nodes and FDG-PET showed no accumulation in those lymph
nodes. Sublobar resection was allowed in cases of complete removal of
the disease using a procedure for a peripheral T1a N0 M0 tumor. Wedge
resection without lymph node assessment was allowed for a pure
ground-glass opacity (GGO) tumor, which was regarded as a node-
negative noninvasive tumor in a prospective study.12 Segmentectomy
with hilar and mediastinal lymph node dissection was allowed for
a GGO-mixed tumor. If lymph node involvement was evident by intraoper-
ative frozen section of any lymph node, the procedure was converted to
standard lobectomy. All of the other patients underwent standard lobec-
tomy. The inclusion criteria included preoperative staging determined by
HRCT and FDG-PET/CT, curative surgery without neoadjuvant chemo-
therapy or radiotherapy, and a definitive histopathologic diagnosis of
lung adenocarcinoma. Patients with incompletely resected tumors (R1 or
R2) and thosewith multiple tumors or previous lung surgery were excluded
from the database. This multicenter study was approved by the institutional
review boards of the participating institutions, all of which waived the re-
quirement for informed consent from individual patients for this retrospec-
tive review of the prospective database.
Table 1 summarizes the characteristics of the 502 patients enrolled in
this study. The mean follow-up period after surgery was 19.8  12.2
months, during which disease recurred in 29 (5.8%) patients. There were
9 (1.8%) local recurrences, including mediastinal lymph node metastasis,
3 (0.6%) local and distant recurrences, and 17 (3.4%) distant recurrences.
The median whole tumor and solid tumor sizes on HRCTwere 2.0 cm and
1.2 cm, respectively. The median SUVmax was 2.0. Lymphatic, vascular,
and pleural invasion was evident in 76 (15.1%), 92 (18.3%), and 56
(11.2%) patients, respectively, and lymph nodes were involved in 38
(7.8%).
High-Resolution Computed Tomography
Sixteen-row multidetector CTwas used to obtain chest images indepen-
dent of subsequent FDG-PET/CT examinations. For high-resolution im-
ages of the tumors, the following parameters were used: 120 kVp, 200
mA, 1 to 2-mm section thickness, 512 3 512-pixel resolution, 0.5 to 1.0-
second scanning time, a high-spatial reconstruction algorithm with
a 20-cm field of view, and mediastinal (level, 40 HU; width, 400 HU)
and lung (level,600 HU; width, 1600 HU) window settings. GGOwas de-
fined as a misty increase in lung attenuation that did not obscure underlying
vascular markings.We defined solid tumor size as the maximum dimension
of the solid component of the lung windows, excluding GGO.11 CT scans1366 The Journal of Thoracic and Cardiovascular Surwere reviewed and tumor sizes determined by radiologists from each insti-
tution for the purpose of this study.
FDG-PET/CT
Patients were instructed to fast for more than 4 hours before intravenous
injection of 74 to 370 MBq FDG and then to relax for at least 1 hour before
FDG-PET/CT scanning. Blood glucose levels were calculated before the
tracer injection to confirm a level of less than150 mg/dL.12 Patients with
blood glucose levels of 150 mg/dL or more were excluded from PET/CT
acquisition. For imaging, Discovery ST (GE Healthcare, Little Chalfont,
United Kingdom), Aquiduo (Toshiba Medical Systems Corporation, To-
chigi, Japan), or Biograph Sensation16 (Siemens Healthcare, Erlangen,
Germany) integrated 3-dimensional PET/CT scanners were used. Low-
dose nonenhanced CT images of 2 to 4-mm section thickness for attenua-
tion correction and localization of lesions identified by PETwere obtained
from the head to the pelvic floor of each patient by following a standard
protocol. Immediately after CT, PET covered the identical axial field of
view for 2 to 4 minutes per table position, depending on the condition of
the patient and the scanner performance. An iterative algorithm with CT-
derived attenuation correction was used to reconstruct all PET images
with a 50-cm field of view. An anthropomorphic body phantom (NEMA
NU2-2001; Data Spectrum Corp, Hillsborough, NC) was used to minimize
variations in SUVs among the institutions. A calibration factor was ana-
lyzed by dividing the actual SUV by the gauged mean SUV in the phantom
background to decrease interinstitutional SUV inconsistencies; the final
SUV used here is referred to as the revised SUVmax.13,14 The
adjustment of interinstitutional variations in SUV narrowed the range
from 0.89 to 1.24 to 0.97 to 1.18 when the SUVmax ratio was expressed
as the SUVmax of each institute relative to the SUVmax of the control
institute. The original SUVmax values were determined by radiologists
from each institution for the purpose of this study.
Follow-up Evaluation
All patients who underwent lung resection were followed up from the
day of surgery. Postoperative follow-up procedures, including a physical
examination and chest radiograph every 3 months and chest and abdominal
CT examinations every 6 months, were performed for the first 2 years. Af-
terward, a physical examination and chest radiograph were performed ev-
ery 6 months, and a chest CT examination was performed every year.
Statistical Analysis
Data are presented as numbers (percents) or the median unless other-
wise stated. Multiple logistic regression analyses were performed to deter-
mine the independent continuous variables related to whole tumor size,
solid tumor size, SUVmax, and carcinoembryonic antigen for prediction
of pathologic lymph node metastasis. In addition, receiver operating char-
acteristic curves of solid tumor size and SUVmax were used for determin-
ing the criteria of pN0. The c2 test for categorical variables was used to
compare frequencies and Fisher’s exact test was applied to small samples.
Disease-free survival (DFS) was defined as the time from the date of sur-
gery until the first event (relapse or death from any cause) or last follow-
up. The Kaplan-Meier method was used to analyze the duration of DFS,
and the log–rank test was used to assess differences in DFS. SPSS software
(version 10.5; SPSS Inc, Chicago, Ill) was used to statistically analyze the
data.RESULTS
Possible predictors of lymph node metastasis were inves-
tigated (Table 2). Multivariate analysis showed that solid tu-
mor size or SUVmax, but not whole tumor size and
carcinoembryonic antigen, were independent predictors of
lymph node metastasis.gery c December 2012
TABLE 1. Patient characteristics
Variable n ¼ 502
Age (y, range) 66 (31-86)
Gender
Male 223 (44.4%)
Female 279 (55.6%)
Whole tumor size (cm, range) 2.0 (0.6-3.0)
Solid tumor size (cm, range) 1.2 (0-3.0)
SUVmax (range) 2.0 (0-27.7)
CEA (ng/mL, range) 2.4 (0-113.8)
Procedure
Lobar resection 320 (63.7%)
Sublobar resection (wedgeþsegmentectomy) 182 (36.3%)
Lymphatic invasion
Negative 426 (84.9%)
Positive 76 (15.1%)
Vascular invasion
Negative 410 (81.7%)
Positive 92 (18.3%)
Pleural invasion
Negative 446 (88.8%)
Positive 56 (11.2%)
Lymph node metastasis
Negative 464 (92.4%)
Positive 38 (7.6%)
SUVmax, Maximum standardized uptake value; CEA, carcinoembryonic antigen.
Tsutani et al General Thoracic Surgery
G
T
SFigure 1 shows the receiver operating characteristic area
under the curve values for solid tumor size and SUVmax
used in determining the criteria of pN0. When using solid
tumor size and SUVmax for predicting pN0, patients with
a solid tumor size of less than 0.8 cm or an SUVmax of
less than 1.5 were observed to have no lymph node metas-
tasis. We defined the predictive criteria of pN0 as a solid tu-
mor size of less than 0.8 cm or an SUVmax of less than 1.5.
Table 3 shows the number of patients who met the criteria
of pN0 as indicated by solid tumor size, SUVmax, and
a combination of the two. Using this combination, the num-
ber of patients expected to have pN0 was 169 (58.5%) of
289 for clinical T1a (2 cm) and 86 (40.4%) of 213 for clin-
ical T1b (2-3 cm) tumors. Figure 2 shows examples of tu-
mors larger than 2 cm that met the predictive criteria of pN0.TABLE 2. Multivariate analysis of possible predictors of lymph node
metastasis
Valuables OR (95% CI) P
Model 1
Whole tumor size (cm) 1.42 (0.76-2.66) .28
SUVmax 1.09 (1.00-1.29) .049
CEA (ng/mL) 1.04 (0.99-1.08) .097
Model 2
Solid tumor size (cm) 2.44 (1.49-4.00) <.001
SUVmax 1.04 (0.93-1.16) .47
CEA (ng/mL) 1.03 (0.99-1.07) .14
OR, Odds ratio; CI, confidence interval; SUVmax, maximum standardized uptake
value; CEA, carcinoembryonic antigen.
FIGURE 1. Receiver operating characteristic area under the curve (AUC)
for detecting lymph node metastasis for solid tumor size (A) and maximum
standardized uptake value (SUVmax) (B). Solid tumor size: AUC, 0.761
(95% confidence interval [CI], 0.703-0.819; P<.001). SUVmax: AUC,
0.761 (95% CI, 0.708-0.814; P<.001).
The Journal of Thoracic and CarA significant difference in DFS for all T1 tumors was
identified between patients with a solid tumor size of less
than 0.8 cm or an SUVmax of less than 1.5 (n ¼ 255;
3-year DFS rate, 100%) and those with a solid tumor size
of 0.8 cm or more and an SUVmax of 1.5 or more
(n ¼ 247; 3-year DFS rate, 81.8%; P< .001) (Figure 3,
A). Even when cases were categorized into cT1a anddiovascular Surgery c Volume 144, Number 6 1367
TABLE 3. Number of patients without nodal metastasis according to
solid tumor size, SUVmax, and a combination of the two
cT1
(n ¼ 502)
cT1a
(n ¼ 289)
cT1b
(n ¼ 213)
Solid tumor size<0.8 cm 187 (37.3%) 131 (45.3%) 56 (26.3%)
SUVmax<1.5 206 (41.0%) 138 (47.8%) 68 (31.9%)
Solid tumor size<0.8 cm
or SUVmax<1.5
255 (50.8%) 169 (58.5%) 86 (40.4%)
SUVmax, Maximum standardized uptake value.
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tween patients with a solid tumor size of less than 0.8 cm
or an SUVmax of less than 1.5 and the remainder
(Figure 3, B and C). Moreover, a significant difference in
DFS was observed between patients with T1a tumor with
a solid tumor size of 0.8 cm or more and an SUVmax of
1.5 or more and those with T1b tumor with a solid tumor
size of less than 0.8 cm or an SUVmax of less than 1.5
(P ¼ .0015; Figure 3, D).
Significant differences in pathologic invasiveness (lym-
phatic, vascular, or pleural invasion) were identified be-
tween patients with a solid tumor size of less than 0.8 cm
or an SUVmax of less than 1.5 and those with a solid tumor
size of 0.8 cm or more and an SUVmax of 1.5 or more
(Table 4); a few patients who met the predictive criteria ofFIGURE 2. Examples of tumors larger than 2 cm that met the predictive
criteria of pathologic node negative. A, Whole tumor size, 2.8 cm; solid tu-
mor size, 0.7 cm; maximum standardized uptake value (SUVmax), 1.8. This
tumor can be treated with sublobar resection, such as right apical segmen-
tectomy. B, Whole tumor size, 2.6 cm; solid tumor size, 1.7 cm; SUVmax,
0.9. This tumor can be treated with sublobar resection, such as left apico-
posterior segmentectomy.
1368 The Journal of Thoracic and Cardiovascular SurpN0 had pathologic invasiveness (9/255, 3.5%). Even in
the cases categorized as cT1a or cT1b, significant differ-
ences in pathologic invasiveness were observed between
the patients with a solid tumor size of less than 0.8 cm or
an SUVmax of less than 1.5 and those with a solid tumor
size of 0.8 cm or more and an SUVmax of 1.5 or more
(Table 4).
DISCUSSION
In 1995, the Lung Cancer Study Group conducted a pro-
spective randomized controlled trial comparing limited re-
section with lobectomy for clinical T1 N0 M0 NSCLC
and concluded that the former resulted in inferior local re-
currence and survival.15 On the other hand, several reports
have described how survival was similar between patients
treated with segmentectomy and those treated with lobec-
tomy.1,4-8 Determining the indications for sublobar
resection requires that intraoperative frozen sections be
examined for all hilar and lobe-specific mediastinal lymph
nodes to confirm the intraoperative N staging as N0.1,4-7
However, intraoperative examination of many lymph
nodes is difficult for thoracic surgeons and pathologists in
the clinical setting. If pN0 can be predicted from
preoperative information, sublobar resection without strict
intraoperative lymph node assessment can be performed
in patients with clinical stage IA NSCLC.
The present study demonstrated the value of using solid
tumor size with HRCT and SUVmax on PET/CT to predict
the status of nodal involvement in clinical stage IA lung ad-
enocarcinoma. We9 reported the usefulness of solid tumor
size defined as the maximum dimension of the solid compo-
nent, excluding GGO, on HRCT compared with that of
whole tumor size for predicting pathologic invasiveness of
tumors or prognosis in clinical stage IA lung adenocarci-
noma. In that study, solid tumor size showed a higher pre-
dictive value for pathologic invasiveness than did whole
tumor size, and it was an independent prognostic factor
for DFS. We9,10,14,16,17 also reported the usefulness of
SUVmax to predict the malignancy grade of tumors with
regard to pathologic invasiveness in lung adenocarcinoma.
Solid tumor size and SUVmax were useful in predicting
both pathologic nodal status and pathologic tumor
invasiveness in the current study. Moreover, we found that
patients with a solid tumor size of less than 0.8 cm or an
SUVmax of less than 1.5 had pN0. There were significant
differences in DFS between patients who met the
predictive criteria of pN0 and those who did not.
Furthermore, the incidence of pathologic invasiveness in
patients who met the predictive criteria of pN0 was very
low. These findings indicate that the predictive criteria of
pN0 were reasonable for choosing a treatment strategy in
clinical stage IA lung adenocarcinoma.
Interestingly, 40.4% of tumors larger than 2 cm and
58.5% of those 2 cm or smaller met the predictive criteriagery c December 2012
FIGURE 3. Disease-free survival (DFS) curves of patients according to the predictive criteria of pathologic node negative using solid tumor size and max-
imum standardized uptake value (SUVmax). A, Three-year DFS rates of 100% and 81.8% for patients with a solid tumor size of less than 0.8 cm or an SUV-
max of less than 1.5 and thosewith a solid tumor size of 0.8 cm or more and an SUVmax of 1.5, respectively (P<.0001) in all T1 tumors. B, Three-year DFS
rate of 100% and 84.2% for patients with a solid tumor size of less than 0.8 cm or an SUVmax of less than 1.5 and those with a solid tumor size of 0.8 cm or
more and an SUVmax of 1.5 or more, respectively (P<.0001) in T1a (2.0 cm) tumors. C, Three-year DFS rate of 100% and 80.1% for patients with a solid
tumor size of less than 0.8 cm or an SUVmax of less than 1.5 and thosewith a solid tumor size of 0.8 cm or more and an SUVmax of 1.5 or more, respectively
(P¼ .003) in T1b (2-3 cm) tumors. D, Three-year DFS rate of 100% and 84.2% for patients with a solid tumor size of less than 0.8 cm or an SUVmax of less
than 1.5 in T1b tumors and those with a solid tumor size of 0.8 cm or more and an SUVmax of 1.5 or more in T1a tumors, respectively (P ¼ .0015).
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for segmentectomy set its indication at T1 N0 M0 NSCLC
of 2 cm or less.1,4-6 The ongoing clinical trials comparing
surgical results between lobectomy and sublobar resection
conducted by the Cancer and Leukemia Group B
(CALGB 140503) and by the Japan Clinical Oncology
Group/West Japan Oncology Group (JCOG0802/
WJOG4607L) also set a T1 N0 M0 NSCLC criterion of 2
cm or smaller for the study subjects.18 However,The Journal of Thoracic and Carapproximately 40% of patients with T1 N0M0 lung adeno-
carcinoma of more than 2 cm might be candidates for sub-
lobar resection according to the present study because such
patients can be predicted as pN0 preoperatively. In fact, no
recurrence was seen in patients with T1b tumor who met the
predictive criteria, regardless of the surgical procedure. Fur-
thermore, the frequency of pathologic invasiveness of T1b
tumors that met the criteria of pN0 was very low. However,
adequate surgical margins are required when performingdiovascular Surgery c Volume 144, Number 6 1369
TABLE 4. Comparison of pathologic invasiveness of tumors and lymph node involvement between patients whomet the criteria of pathologic node
negative and those who did not
All tumors
(n ¼ 502)
Solid tumor size<0.8 cm or
SUVmax<1.5 (n ¼ 255)
Solid tumor size  0.8 cm
and SUVmax 1.5 (n¼ 247) P
LY 4 (1.6%) 73 (29.6%) <.001
V 4 (1.6%) 89 (36.0%) <.001
PL 3 (1.2%) 55 (22.3%) <.001
LY or Vor PL 9 (3.5%) 131 (53.0%) <.001
N 0 (0%) 38 (15.4%) <.001
T1a tumors
(n ¼ 289)
Solid tumor size<0.8 cm or
SUVmax<1.5 (n ¼ 169)
Solid tumor size  0.8 cm
and SUVmax 1.5 (n¼ 120) P
LY 3 (1.8%) 34 (28.3%) <.001
V 4 (2.4%) 33 (27.5%) <.001
PL 2 (1.2%) 24 (20.0%) <.001
LY or Vor PL 7 (4.1%) 59 (49.2%) <.001
N 0 (0%) 16 (13.3%) <.001
T1b tumors
(n ¼ 213)
Solid tumor size<0.8 cm or
SUVmax<1.5 (n ¼ 86)
Solid tumor size  0.8 cm
and SUVmax 1.5 (n¼ 127) P
LY 1 (1.2%) 39 (30.7%) <.001
V 0 (0%) 56 (44.1%) <.001
PL 1 (1.2%) 31 (24.4%) <.001
LY or Vor PL 2 (2.3%) 72 (56.7%) <.001
N 0 (0%) 22 (17.3%) <.001
SUVmax, Maximum standardized uptake value; LY, lymphatic invasion; V, vascular invasion; PL, pleural invasion.
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section with adequate surgical margins, we recommend seg-
mentectomy, not wedge resection, for T1b tumors that meet
the criteria of pN0. To provide an adequate surgical margin
for T1b tumors by wedge resection is difficult. Local recur-
rence must be avoided. When performing lobar resection
for tumors that meet the predictive criteria of pN0, system-
atic lymph node dissection such as mediastinal lymph node
dissection is not always needed. On the other hand, when
performing sublobar resection in patients with tumors of 2
cm or less, wedge resection and segmentectomy with ample
surgical margins can be permitted. The extent of resection
can be determined according to the tumor size and location.
Lobe-specific lymph node dissection or sampling can be al-
lowed for tumors that meet the criteria of pN0. Systematic
lymph node dissection is not always needed for these tu-
mors. The use of solid tumor size and SUVmax allows
many more patients to be identified, who may benefit
from the maintenance of lung function that results from se-
lecting sublobar resection rather than can be identified sim-
ply on the basis of peripheral small nodules of 2 cm or less.
The proportion of patients with lung adenocarcinoma of 2
cm or less who did not meet the predictive criteria of pN0
was approximately 40%. There are some risks of lymph
node metastasis in small lung adenocarcinoma that do not
meet the predictive criteria of pN0. When sublobar resec-
tion is performed in such cases, intraoperative lymph
node assessment, such as examination of frozen sections,1370 The Journal of Thoracic and Cardiovascular Suris mandatory, and wedge resection cannot be recommended
because such a procedure does not allow an approach to the
hilar lymph nodes for assessment. If lymph node metastasis
is intraoperatively shown, sublobar resection should be con-
verted to standard lobectomy with systematic lymph node
dissection.
One of the limitations of this multicenter study using PET
is the wide variation in SUVamong institutions. Many fac-
tors such as preparation procedures, scan acquisition, image
reconstruction, and data analysis can affect SUV. In this
study, we used an anthropomorphic body phantom to min-
imize interinstitutional variability in SUV. When perform-
ing subgroup analyses of DFS from each institution, DFS
of patients with a solid tumor size of less than 0.8 cm or
an SUVmax of less than 1.5 was significantly better than
that of patients with a solid tumor size of 0.8 cm or more
and an SUVmax of 1.5 or more (data not shown). Moreover,
when using the original SUVmax values, multivariate logis-
tic regression analysis showed that SUVmax was an inde-
pendent predictor of lymph node metastasis, and DFS of
patients with a solid tumor size of less than 0.8 cm or an
SUVmax of less than 1.5 was significantly better than that
of those with a solid tumor size of 0.8 cm or more and an
SUVmax of 1.5 or more (data not shown). These findings
are important to other institutions that may use our criteria
of pN0.
This study had several limitations. Because the follow-up
period was short, long-term follow-up is needed to confirmgery c December 2012
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measure solid tumor size, especially with a large GGO com-
ponent. Because this was a retrospective study, a validation
cohort study is required to confirm our pN0 predictive cri-
teria of solid tumor size on HRCT and SUVmax on FDG-
PET/CT.
CONCLUSIONS
Preoperative solid tumor size on HRCT and SUVmax on
FDG-PET/CT are useful for prediction of pN0 in clinical
stage IA lung adenocarcinoma. The pN0 predictive criteria
of solid tumor size less than 0.8 cm or SUVmax less than 1.5
may be helpful for avoiding systematic lymphadenectomy
in patients with clinical stage IA lung adenocarcinoma.
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